SVIP (small VCP interacting protein) is a multifunctional regulatory protein that primarily functions as a negative regulator of the endoplasmic reticulum-associated degradation (ERAD) pathway 1. SVIP competes with AMFR/gp78 for binding to VCP/p97, thereby inhibiting the formation of AMFR/gp78-VCP/p97 complexes required for degradation of ERAD substrates 1. Beyond ERAD regulation, SVIP plays critical roles in lysosomal dynamics and autophagy, where it specifically recruits VCP to lysosomes and is essential for lysosomal dynamic stability and autophagosomal-lysosomal fusion 2. SVIP also regulates adrenal steroidogenesis, with appropriate expression levels enhancing cortisol and DHEA biosynthesis by upregulating steroidogenic enzymes and cholesterol metabolism proteins 3. The protein demonstrates significant disease relevance, as SVIP mutations cause muscle wasting and neuromuscular degeneration 2, while its dysregulation affects cancer cell behavior, with silencing enhancing proliferation in some breast cancer cells and increasing migration in pancreatic cancer cells 14. Clinically, SVIP shows protective effects against liver fibrosis through autophagy activation 5 and its overexpression can extend lifespan in stress-dependent conditions 2, suggesting therapeutic potential.